Drug Profile
Picoplatin
Alternative Names: AMD 473; JM 473; NX 473; ZD 0473Latest Information Update: 22 Jan 2013
Price :
$50
*
At a glance
- Originator Johnson Matthey
- Developer Poniard Pharmaceuticals
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued Colorectal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours
Most Recent Events
- 30 Mar 2012 Discontinued - Phase-I for Solid tumours in USA (PO)
- 30 Mar 2012 Discontinued - Phase-II for Colorectal cancer (combination therapy, first-line therapy, metastatic disease) in Russia (IV)
- 30 Mar 2012 Discontinued - Phase-II for Ovarian cancer (second-line therapy) in Europe (IV)